Summary
What do they do? New Eyes for the Needy, EIN 22-1539720, pays for basic single-vision or lined-bifocal glasses for eligible U.S. applicants with a current prescription. It reports serving all 50 states, DC and Puerto Rico. More
Why this approach interests us
- New Eyes supplies low-cost prescription glasses to financially eligible people who might otherwise remain uncorrected.
Our main reservations
- The utility bridge is transferred from a small uncontrolled Zambian study, while wear, counterfactual correction and gift additionality are analyst judgments.
What do you get for your dollar?
This is a very-low-confidence model of a $100,000 unrestricted gift, not measured impact or a verified marginal offer. A 5% favorable scenario supplies 25.8% of expected health; removing it raises the donor estimate to $100,714. Hypothetical 2% Bay and 0.25% SF allocation shares imply $3.93 million and $31.46 million per 10 local QALYs, but actual local recipient shares are unknown. Inspect all formulas, inputs and scenarios.
- national donor estimate
- $78,651 / 10 QALYs — Weighted ordinary-gift scenario; very low confidence.
- without favorable tail
- $100,714 / 10 QALYs — Central and cautious-positive scenarios renormalized.
- gross associated resources
- $219,881 / 10 QALYs — Includes illustrative exam/refraction and application-fee resources.
- funding room
- Unverified — Falling reported reach and deficits do not establish scalable unmet demand.
1. What do they do?
New Eyes for the Needy, EIN 22-1539720, pays for basic single-vision or lined-bifocal glasses for eligible U.S. applicants with a current prescription. It reports serving all 50 states, DC and Puerto Rico.
Confirm eligibility and prescription
Applicants use a referring agency or direct application. A prescription generally must be dated within 24 months; California's limited online verification is not a comprehensive eye exam.
Issue and redeem a voucher
Approved applicants order one basic pair. Application, voucher and glasses are one recipient-course, not separate impact units.
Value sustained correction
Health requires the pair to fit, be worn and correct vision that would otherwise remain uncorrected for a finite period.
Scope of this review. The model covers an unrestricted whole-organization gift and the domestic glasses pathway. Overseas donated frames receive no health credit. Historical expense per reported U.S. individual—not the optical component alone—sets cash throughput.
2. Monitoring and information sharing
Reported U.S. recipients, FY2024–FY2026
Primary filings and program rules. The organization reported 21,837, 16,527 and 15,204 financially needy U.S. individuals receiving glasses across the three years.
Our assessment. This supports delivery and historical average cost, not verified unique recipients, counterfactual correction or marginal gift impact.
41 Zambian refraction patients followed for six months
Uncontrolled before/after study. Mean EQ-5D rose from 0.850 to 0.925.
Our assessment. The 0.075 change is not causal and may reflect unusually severe presenting impairment. Our 0.030 central U.S. transfer remains a judgment.
Adults randomized to ready-made versus custom spectacles
Randomized adult spectacle trial. Spectacles improved vision-specific quality of life in both groups.
Our assessment. This supports benefit plausibility but does not identify a generic U.S. utility gain or New Eyes' incremental effect.
3. Qualitative assessment
New Eyes supplies low-cost prescription glasses to financially eligible people who might otherwise remain uncorrected.
Key reservations
- Reported individuals are not independently verified unique recipients, and issued vouchers may expire.
- A current prescription and eye exam are prerequisites whose resource cost is not in the donor ledger.
- The model lacks measured fit, wear, breakage, replacement and sustained utility outcomes.
- No Bay/SF volume, local restriction commitment or verified marginal expansion plan is published.
Benefits not included in our estimate
- Education, employment, caregiver and safety benefits without a non-overlapping causal bridge.
- Overseas donated-frame benefits.
- Retail-price savings as if they were QALYs or economic resource costs.
- Unmeasured value of the prerequisite eye examination.
4. What do you get for your dollar?
A $100,000 gift yields 12.714 expected U.S.-wide QALYs in our weighted model.
Historical whole-organization expense per reported U.S. individual was $60.19, $65.89 and $75.33 across FY2024–FY2026. The public $24–$25 optical figure excludes the rest of an ordinary gift and the prerequisite exam. Scenario weights are subjective judgments, not empirical probabilities.
A better life is our comparison unit of 10 additional quality-adjusted life years (QALYs), potentially spread across people. These are uncertain estimates, not measured returns or verified donation offers.
How we calculate the estimate
Weighted ordinary-gift model: Recipients = gift / historical whole-organization expense per reported individual. QALYs = recipients × funding additionality × (otherwise uncorrected × wear × utility gain × discounted duration − shared harm) × dispensing-delay discount; then sum scenario QALYs by weight.
12.7144 expected QALYs; $100,000 × 10 / 12.7144 = $78,650.90.
Model inputs and assumptions
- Historical expense per reported individual
- $65.89 central (range: $60.19–$75.33). Whole-organization expenses divided by reported U.S. individuals in three fiscal years. Primary filings; denominator not independently deduplicated.
- Funding additionality
- 50% central (range: 25–75%). Share of gift-funded courses that are genuinely additional rather than replacing other resources. Analyst judgment.
- Otherwise-uncorrected share
- 70% central (range: 50–90%). Applicants may find other charitable, public, insurance or household financing. Analyst judgment.
- Sustained wear
- 80% central (range: 50–80%). Correct fit, receipt, use and persistence are not measured for the modeled cohort. Analyst judgment.
- Utility gain while worn
- 0.030 central (range: 0.010–0.050). Haircut from an uncontrolled 0.075 EQ-5D change among 41 followed Zambian patients; not a U.S. causal estimate. Very-low-confidence transfer.
- Effective duration
- 1 year central (range: 0.5–1.5 years). Finite correction period after delay; no lifetime extrapolation. Analyst judgment.
- Hypothetical local allocation
- 2% Bay; 0.25% SF (range: Bay 1–4%; SF 0.1–0.5%). No primary Bay/SF recipient counts or restricted-gift commitment. SF is nested inside Bay. Sensitivity only.
How much could the estimate change?
- Weighted national estimate: $78,651 donor / $219,881 gross per 10 QALYs. Includes 5% favorable, 75% central and 20% cautious-positive weight.
- No favorable scenario: $100,714 donor / $286,543 gross per 10 QALYs. The remaining two scenarios are renormalized; this shows the favorable tail's leverage.
- Hypothetical Bay 2%: $3.93 million donor per 10 Bay QALYs. Allocation arithmetic only, not an observed local share.
- Hypothetical SF 0.25%: $31.46 million donor per 10 SF QALYs. Nested within the Bay sensitivity; not an SF recommendation.
- No additional redeemed glasses: No finite positive price. If the gift merely replaces funding or recipients would otherwise obtain correction, incremental QALYs are zero.
Uncertainty. The weights do not define a confidence interval. The 5% favorable case contributes 25.8% of expected health. Gross-resource figures use unobserved exam costs and fee incidence, and the duration discount is a short-horizon analyst approximation.
5. Funding and previous grants
Verify redeemed-glasses capacity, otherwise-uncorrected recipients, a U.S. utility bridge, full exam resources and Bay/SF delivery before treating this as a funding recommendation.
Reported U.S. reach fell from 21,837 to 16,527 to 15,204 while the organization reported recent deficits and $4.52 million in net assets. These facts motivate diligence but establish neither a waitlist nor marginal capacity. Ask for state-level issued, redeemed and expired vouchers; turnaways; optical-lab capacity; unrestricted-gift allocation; exam financing; and a written local designation option.
This review does not establish a verified marginal funding offer or a complete history of grants.
Opens the organization’s giving page. A general donation may not fund the specific activity modeled here; confirm allocation with the recipient.
6. Sources
- FY2023–24 Form 990. New Eyes for the Needy. Primary organization-posted filing. Published: Fiscal year ended March 31, 2024; retrieved: September 10, 2026.
- FY2023–24 audited financial statements. New Eyes for the Needy. Primary audited financial statements. Published: Fiscal year ended March 31, 2024; retrieved: September 10, 2026.
- FY2024–25 Form 990 filing. IRS via ProPublica Nonprofit Explorer. Primary tax filing reproduction. Published: Fiscal year ended March 31, 2025; retrieved: September 10, 2026.
- FY2025–26 Form 990. New Eyes for the Needy. Organization-posted return; IRS processing not separately verified. Published: Fiscal year ended March 31, 2026; retrieved: September 10, 2026.
- Application rules. New Eyes for the Needy. Primary program rules. Published: Current page; retrieved: September 10, 2026.
- $8,000 Delta Gamma grant announcement. New Eyes for the Needy. Primary restricted optical-cost claim. Published: November 23, 2025; retrieved: September 10, 2026.
- The impact of refractive error on the quality of life of patients in rural Zambia. Griffiths et al.. Peer-reviewed uncontrolled before/after study. Published: 2014; retrieved: September 10, 2026.
- Vision and quality of life following ready-made spectacles. Keay et al.. Peer-reviewed randomized adult spectacle trial. Published: 2013; retrieved: September 10, 2026.
Annual expenses: years and sources
Average annual expenses (three consecutive fiscal years): Not available. Organization size is separate from the modeled cost-effectiveness of a donation.
New Eyes for the Needy
Three years of organization-level expenses have not yet been verified for this report. No other organization or fiscal sponsor budget has been substituted.